TetraGraph receives regulatory approval and additional order from South Korea

This second order is part of the contracted sales volume of the South Korean market. There are more than 3,000 hospitals in South Korea and more than 1.3 million operations are performed annually of which muscle relaxants are used in more than half of them. Senzime's marketing team recently conducted a TetraGraph training for over 80 salespeople at the South Korean distributor, who expects a successful launch in the country.  

"Senzime has begun the global rollout of TetraGraph and in South Korea we have a strong start. We are now working to ensure delivery capacity so that we can meet the interest in TetraGraph in all markets were we currently have distribution agreements, says Pia Renaudin, CEO at Senzime

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com       

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com